<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03015740</url>
  </required_header>
  <id_info>
    <org_study_id>2016-0332</org_study_id>
    <secondary_id>NCI-2017-00324</secondary_id>
    <secondary_id>2016-0332</secondary_id>
    <nct_id>NCT03015740</nct_id>
  </id_info>
  <brief_title>Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer</brief_title>
  <official_title>Phase I/II Trial of MGCD516 Combined With Nivolumab in Patients With Advanced Clear Cell Renal Cell Cancer That Progressed on Prior VEGF-Targeted Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the side effects of sitravatinib and how well it works with&#xD;
      nivolumab in treating patients with kidney cancer that has spread to other places in the&#xD;
      body. Sitravatinib may stop the growth of tumor cells by blocking some of the enzymes needed&#xD;
      for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the&#xD;
      body's immune system attack the cancer, and may interfere with the ability of tumor cells to&#xD;
      grow and spread. Giving sitravatinib and nivolumab may work better in treating patients with&#xD;
      kidney cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the toxicities (defined as a grade 3 or 4 National Cancer Institute [NCI]&#xD;
      non-hematologic or hematologic adverse event, within 12 weeks from treatment initiation), and&#xD;
      efficacy (defined as achieving complete remission, partial remission, or stable disease&#xD;
      within 6 weeks) of sitravatinib (MGCD516) when administered orally (PO) daily in combination&#xD;
      with standard dose nivolumab 240 mg/kg every 2 weeks.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate the overall survival (OS), progression-free survival (PFS) times, objective&#xD;
      response rates (ORR), and quality of life (QOL) of patients with advanced clear cell renal&#xD;
      cell cancer (RCC) treated with the combination of MGCD516 and nivolumab.&#xD;
&#xD;
      II. Evaluate potential biomarkers for patient stratification and treatment response,&#xD;
      including genetic analysis, serum cytokines and chemokines, as well as tumor antigen-specific&#xD;
      immune responses, such as antibody and T cell responses, as surrogates for anti-tumor&#xD;
      activity.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive sitravatinib PO once daily (QD) on days 1-14 and receive nivolumab&#xD;
      intravenously (IV) over 60 minutes on day 1 starting cycle 2. Cycles repeat every 14 days for&#xD;
      cycles 1-6 and then every 28 days for subsequent cycles in the absence of disease progression&#xD;
      or unacceptable toxicity. Patients who receive at least 6 infusions of nivolumab with no dose&#xD;
      limiting toxicities (DLTs) related to nivolumab, may then receive nivolumab every 4 weeks.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 30 days and then every 3&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 23, 2017</start_date>
  <completion_date type="Actual">September 6, 2022</completion_date>
  <primary_completion_date type="Actual">September 6, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Defined as National Cancer Institute grade 3 or 4 liver, lung, gastrointestinal or endocrine toxicity, or myelosuppression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy (defined as achieving complete remission, partial remission or stable disease)</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Defined as achieving complete remission, partial remission or stable disease as determined by Response Evaluation Criteria in Solid Tumors version 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival time</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Unadjusted distributions of the time-to-event outcomes will be estimated using the method of Kaplan and Meier and their relationship to prognostic covariates will be evaluated by Bayesian piecewise exponential survival regression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival time</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Unadjusted distributions of the time-to-event outcomes will be estimated using the method of Kaplan and Meier and their relationship to prognostic covariates will be evaluated by Bayesian piecewise exponential survival regression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Unadjusted distributions of the time-to-event outcomes will be estimated using the method of Kaplan and Meier and their relationship to prognostic covariates will be evaluated by Bayesian piecewise exponential survival regression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Functional Assessment of Cancer Therapy (FACT) will be used to measure cancer-specific health-related quality of life</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>The Medical Outcomes Study 12-item short-form survey (SF-12) will be used to measure general quality of life</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Clear Cell Renal Cell Carcinoma</condition>
  <condition>Metastatic Kidney Carcinoma</condition>
  <condition>Stage III Renal Cell Cancer AJCC v7</condition>
  <condition>Stage IV Renal Cell Cancer AJCC v7</condition>
  <arm_group>
    <arm_group_label>Treatment (sitravatinib, nivolumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive sitravatinib PO QD on days 1-14 and receive nivolumab IV over 60 minutes on day 1 starting cycle 2. Cycles repeat every 14 days for cycles 1-6 and then every 28 days for subsequent cycles in the absence of disease progression or unacceptable toxicity. Patients who receive at least 6 infusions of nivolumab with no DLTs related to nivolumab, may then receive nivolumab every 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (sitravatinib, nivolumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (sitravatinib, nivolumab)</arm_group_label>
    <other_name>BMS-936558</other_name>
    <other_name>MDX-1106</other_name>
    <other_name>NIVO</other_name>
    <other_name>ONO-4538</other_name>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (sitravatinib, nivolumab)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (sitravatinib, nivolumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitravatinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (sitravatinib, nivolumab)</arm_group_label>
    <other_name>MGCD516</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histologically or cytologically confirmed metastatic/advanced clear cell&#xD;
             RCC, or RCC with a clear cell component, who have received 1 or 2 prior&#xD;
             anti-angiogenic therapy regimens (+/- cytokine therapy with interleukin-2 or&#xD;
             interferon-alfa) in the advanced or metastatic setting; examples of anti-angiogenic&#xD;
             agents include, but are not limited to, sorafenib, sunitinib, pazopanib, axitinib, and&#xD;
             bevacizumab&#xD;
&#xD;
          -  There must be evidence of progression on or after last treatment regimen received and&#xD;
             within 6 months of enrollment&#xD;
&#xD;
          -  Patients must have at least one measurable site of disease, defined as a lesion that&#xD;
             can be accurately measured in at least one dimension (longest diameter to be recorded)&#xD;
             and measures &gt;= 15 mm with conventional techniques or &gt;= 10 mm with more sensitive&#xD;
             techniques such as magnetic resonance imaging (MRI) or spiral computed tomography (CT)&#xD;
             scan; if the patient has had previous radiation to the marker lesion(s), there must be&#xD;
             evidence of progression since the radiation&#xD;
&#xD;
          -  Karnofsky performance status &gt;= 70&#xD;
&#xD;
          -  Hemoglobin &gt;= 9 g/dl (treatment allowed) (within 14 days prior to study entry)&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/uL (within 14 days prior to study entry)&#xD;
&#xD;
          -  Platelets &gt;= 100,000/uL (within 14 days prior to study entry)&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 mg/dl (within 14 days prior to study entry)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) or&#xD;
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =&lt; 2.5 x&#xD;
             institutional upper limit of normal (ULN), except in known hepatic metastasis, wherein&#xD;
             may be &lt; 5 x ULN (within 14 days prior to study entry)&#xD;
&#xD;
          -  Serum creatinine =&lt; 1.5 x ULN (as long as patient does not require dialysis); a) may&#xD;
             receive transfusion b) if creatinine is not &lt; 1.5 x ULN, then calculate by&#xD;
             Cockcroft-Gault methods or local institutional standard and creatinine clearance&#xD;
             (CrCl) must be &gt;= 40 mL/kg/1.73 m^2 (within 14 days prior to study entry)&#xD;
&#xD;
          -  International normalized ratio (INR) and partial thromboplastin time (PTT) =&lt; 1.5 x&#xD;
             ULN within 14 days prior to study entry; therapeutic anticoagulation with warfarin is&#xD;
             allowed if target INR =&lt; 3 on a stable dose of warfarin or on a stable dose of low&#xD;
             molecular weight (LMW) heparin for &gt; 2 weeks (14 days) at the time of enrollment&#xD;
&#xD;
          -  Female patients of childbearing potential (not postmenopausal for at least 12 months&#xD;
             and not surgically sterile) must have a negative serum or urine pregnancy test&#xD;
             (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin&#xD;
             [HCG]) within 14 days before study entry; pregnancy test must be repeated if performed&#xD;
             &gt; 14 days before starting study drug&#xD;
&#xD;
          -  Women must not be breastfeeding&#xD;
&#xD;
          -  Patients with a history of major psychiatric illness must be judged (by the treating&#xD;
             physician) able to fully understand the investigational nature of the study and the&#xD;
             risks associated with the therapy&#xD;
&#xD;
          -  Patients with controlled brain metastases are allowed on protocol if they had solitary&#xD;
             brain metastases that was surgically resected or treated with radiosurgery or gamma&#xD;
             knife, without recurrence or edema for 1 month (4 weeks)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients must not have any other malignancies within the past 2 years except for in&#xD;
             situ carcinoma of any site, or adequately treated (without recurrence post-resection&#xD;
             or post-radiotherapy) carcinoma of the cervix or basal or squamous cell carcinomas of&#xD;
             the skin or active non-threatening second malignancy that would not, in the&#xD;
             investigator's opinion, potentially interfere with the patient's ability to&#xD;
             participate and/or complete this trial; examples include but not limited to:&#xD;
             urothelial cancer grade Ta or T1, adenocarcinoma of the prostate treated by active&#xD;
             surveillance&#xD;
&#xD;
          -  Patients currently receiving anticancer therapies or who have received anticancer&#xD;
             therapies within 2 weeks (14 days) from enrollment into this study (including&#xD;
             chemotherapy and targeted therapy) are excluded; also, patients who have completed&#xD;
             palliative radiation therapy more than 14 days prior to the first dose of MGCD516 are&#xD;
             eligible&#xD;
&#xD;
          -  Patients, who have had a major surgery or significant traumatic injury (injury&#xD;
             requiring &gt; 4 weeks [28 days] to heal) within 4 weeks (28 days) of start of study&#xD;
             drug, patients who have not recovered from the side effects of any major surgery&#xD;
             (defined as requiring general anesthesia) or patients that are expected to require&#xD;
             major surgery during the course of the study&#xD;
&#xD;
          -  Patients who have been previously treated with mTOR inhibitors such as everolimus and&#xD;
             temsirolimus, or with c-MET inhibitors such as cabozantinib&#xD;
&#xD;
          -  Patients who have organ allografts&#xD;
&#xD;
          -  Known or suspected autoimmune disease; patients with a history of inflammatory bowel&#xD;
             disease (including Crohn's disease and ulcerative colitis) and autoimmune disorders&#xD;
             such as rheumatoid arthritis, systemic progressive sclerosis (scleroderma), systemic&#xD;
             lupus erythematosus or autoimmune vasculitis (e.g., Wegener's granulomatosis) are&#xD;
             excluded from this study; patients with a history of Hashimoto's thyroiditis only&#xD;
             requiring hormone replacement, type I diabetes, or psoriasis not requiring systemic&#xD;
             treatment, or conditions not expected to recur in the absence of an external trigger&#xD;
             are allowed to participate&#xD;
&#xD;
          -  Known history of testing positive for human immunodeficiency virus (HIV) or known&#xD;
             acquired immunodeficiency syndrome (AIDS)&#xD;
&#xD;
          -  Any underlying medical condition, which in the opinion of the investigator, will make&#xD;
             the administration of study drug hazardous or obscure the interpretation of adverse&#xD;
             events, such as a condition associated with frequent diarrhea, uncontrolled nausea,&#xD;
             vomiting, malabsorption syndrome or small bowel resection that may significantly alter&#xD;
             the absorption of MGCD516&#xD;
&#xD;
          -  Patients must not have received prior anticancer therapy with any immune checkpoint&#xD;
             inhibitors such as anti-CLTA-4, anti-PD1, or anti-PD-L1&#xD;
&#xD;
          -  Patients receiving any concomitant systemic therapy for renal cell cancer are excluded&#xD;
&#xD;
          -  Patients must not be scheduled to receive another experimental drug while on this&#xD;
             study&#xD;
&#xD;
          -  Patients who are on high dose steroid (e.g., &gt; 10 mg prednisone daily or equivalent)&#xD;
             or other more potent immune suppression medications (e.g., infliximab); topical,&#xD;
             inhaled, intra-articular, ocular, or intranasal corticosteroids (with minimal systemic&#xD;
             absorption) are allowed; a brief course (=&lt; 48 hours) of systemic corticosteroids for&#xD;
             prophylaxis (e.g., from contrast dye allergy) is permitted&#xD;
&#xD;
          -  Patients who have any severe and/or uncontrolled medical conditions or other&#xD;
             conditions that could affect their participation in the study such as: symptomatic&#xD;
             congestive heart failure of New York Heart Association class III or IV; unstable&#xD;
             angina pectoris, symptomatic congestive heart failure, myocardial infarction within 6&#xD;
             months of start of study drug, serious uncontrolled cardiac arrhythmia or any other&#xD;
             clinically significant cardiac disease; severely impaired lung function as defined as&#xD;
             oxygen (O2) saturation that is 88% or less at rest on room air; uncontrolled diabetes&#xD;
             as defined by blood glucose &gt; 200 mg/dl (11.1 mmol/l); systemic fungal, bacterial,&#xD;
             viral, or other infection that is not controlled (defined as exhibiting ongoing&#xD;
             signs/symptoms related to the infection and without improvement) despite appropriate&#xD;
             antibiotics or other treatment; liver disease such as cirrhosis or chronic active&#xD;
             hepatitis; positive test for hepatitis B virus (HBV) using HBV surface antigen (HBV&#xD;
             sAg) test or positive test for hepatitis C virus (HCV) using HCV ribonucleic acid&#xD;
             (RNA) or HCV antibody test indicating acute or chronic infection&#xD;
&#xD;
          -  Patients must not have history of other diseases, metabolic dysfunction, physical&#xD;
             examination finding, or clinical laboratory finding giving reasonable suspicion of a&#xD;
             disease or condition that contraindicates the use of MGCD516 or nivolumab or that&#xD;
             might affect the interpretation of the results of the study or render the subject at&#xD;
             high risk from treatment complications&#xD;
&#xD;
          -  Patients should not receive immunization with attenuated live vaccines within one week&#xD;
             (7 days) of study entry or during study period&#xD;
&#xD;
          -  Uncontrolled brain or leptomeningeal metastases, including patients who continue to&#xD;
             require glucocorticoids for brain or leptomeningeal metastases&#xD;
&#xD;
          -  Female patients who are pregnant or breast feeding, or adults of reproductive&#xD;
             potential who are not using effective birth control methods; if barrier contraceptives&#xD;
             are being used, these must be continued throughout the trial by both sexes; hormonal&#xD;
             contraceptives are not acceptable as a sole method of contraception; (women of&#xD;
             childbearing potential must have a negative urine or serum pregnancy test within 14&#xD;
             days prior to study entry; pregnancy test must be repeated if performed &gt; 14 days&#xD;
             before administration of MGCD516)&#xD;
&#xD;
          -  Any patients who cannot be compliant with the appointments required in this protocol&#xD;
             must not be enrolled in this study&#xD;
&#xD;
          -  Concurrent therapy with medications known to significantly prolong the QT interval&#xD;
             and/or associated with increased risk for Torsade de Pointes arrhythmia; the principal&#xD;
             investigator (PI) is the final arbiter in questions related to eligibility&#xD;
&#xD;
          -  Patients with left ventricular ejection fraction (LVEF) &lt; 40%&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pavlos Msaoel</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center</description>
  </link>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>January 6, 2017</study_first_submitted>
  <study_first_submitted_qc>January 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2017</study_first_posted>
  <last_update_submitted>April 27, 2023</last_update_submitted>
  <last_update_submitted_qc>April 27, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>July 20, 2023</submitted>
    <returned>August 10, 2023</returned>
    <submitted>August 16, 2023</submitted>
    <returned>September 8, 2023</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03015740
org study id: 2016-0332
secondary id: NCI-2017-00324
secondary id: 2016-0332
nct id: NCT03015740
lead sponsor: 
collaborator: 
has dmc: No
is fda regulated drug: Yes
is fda regulated device: No
This phase I/II trial studies the side effects of sitravatinib and how well it works with
      nivolumab in treating patients with kidney cancer that has spread to other places in the
      body. Sitravatinib may stop the growth of tumor cells by blocking some of the enzymes needed
      for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the
      body's immune system attack the cancer, and may interfere with the ability of tumor cells to
      grow and spread. Giving sitravatinib and nivolumab may work better in treating patients with
      kidney cancer.
PRIMARY OBJECTIVES:

      I. To determine the toxicities (defined as a grade 3 or 4 National Cancer Institute [NCI]
      non-hematologic or hematologic adverse event, within 12 weeks from treatment initiation), and
      efficacy (defined as achieving complete remission, partial remission, or stable disease
      within 6 weeks) of sitravatinib (MGCD516) when administered orally (PO) daily in combination
      with standard dose nivolumab 240 mg/kg every 2 weeks.

      SECONDARY OBJECTIVES:

      I. To estimate the overall survival (OS), progression-free survival (PFS) times, objective
      response rates (ORR), and quality of life (QOL) of patients with advanced clear cell renal
      cell cancer (RCC) treated with the combination of MGCD516 and nivolumab.

      II. Evaluate potential biomarkers for patient stratification and treatment response,
      including genetic analysis, serum cytokines and chemokines, as well as tumor antigen-specific
      immune responses, such as antibody and T cell responses, as surrogates for anti-tumor
      activity.

      OUTLINE:

      Patients receive sitravatinib PO once daily (QD) on days 1-14 and receive nivolumab
      intravenously (IV) over 60 minutes on day 1 starting cycle 2. Cycles repeat every 14 days for
      cycles 1-6 and then every 28 days for subsequent cycles in the absence of disease progression
      or unacceptable toxicity. Patients who receive at least 6 infusions of nivolumab with no dose
      limiting toxicities (DLTs) related to nivolumab, may then receive nivolumab every 4 weeks.

      After completion of study treatment, patients are followed up at 30 days and then every 3
      months.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Incidence of adverse events
time frame: Up to 12 weeks
description: Defined as National Cancer Institute grade 3 or 4 liver, lung, gastrointestinal or endocrine toxicity, or myelosuppression.
measure: Efficacy (defined as achieving complete remission, partial remission or stable disease)
time frame: Up to 6 weeks
description: Defined as achieving complete remission, partial remission or stable disease as determined by Response Evaluation Criteria in Solid Tumors version 1.1.
measure: Progression free survival time
time frame: Up to 6 years
description: Unadjusted distributions of the time-to-event outcomes will be estimated using the method of Kaplan and Meier and their relationship to prognostic covariates will be evaluated by Bayesian piecewise exponential survival regression.
measure: Overall survival time
time frame: Up to 6 years
description: Unadjusted distributions of the time-to-event outcomes will be estimated using the method of Kaplan and Meier and their relationship to prognostic covariates will be evaluated by Bayesian piecewise exponential survival regression.
measure: Objective response rate
time frame: Up to 6 years
description: Unadjusted distributions of the time-to-event outcomes will be estimated using the method of Kaplan and Meier and their relationship to prognostic covariates will be evaluated by Bayesian piecewise exponential survival regression.
measure: The Functional Assessment of Cancer Therapy (FACT) will be used to measure cancer-specific health-related quality of life
time frame: Up to 6 years
description: The Medical Outcomes Study 12-item short-form survey (SF-12) will be used to measure general quality of life
arm group label: Treatment (sitravatinib, nivolumab)
arm group type: Experimental
description: Patients receive sitravatinib PO QD on days 1-14 and receive nivolumab IV over 60 minutes on day 1 starting cycle 2. Cycles repeat every 14 days for cycles 1-6 and then every 28 days for subsequent cycles in the absence of disease progression or unacceptable toxicity. Patients who receive at least 6 infusions of nivolumab with no DLTs related to nivolumab, may then receive nivolumab every 4 weeks.
intervention type: Other
intervention name: Laboratory Biomarker Analysis
description: Correlative studies
arm group label: Treatment (sitravatinib, nivolumab)
intervention type: Biological
intervention name: Nivolumab
description: Given IV
arm group label: Treatment (sitravatinib, nivolumab)
other name: BMS-936558
other name: MDX-1106
other name: NIVO
other name: ONO-4538
other name: Opdivo
intervention type: Other
intervention name: Quality-of-Life Assessment
description: Ancillary studies
arm group label: Treatment (sitravatinib, nivolumab)
other name: Quality of Life Assessment
intervention type: Other
intervention name: Questionnaire Administration
description: Ancillary studies
arm group label: Treatment (sitravatinib, nivolumab)
intervention type: Drug
intervention name: Sitravatinib
description: Given PO
arm group label: Treatment (sitravatinib, nivolumab)
other name: MGCD516
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Pavlos Msaoel
role: Principal Investigator
affiliation: M.D. Anderson Cancer Center
facility: 
country: United States
url: http://www.mdanderson.org
description: MD Anderson Cancer Center
responsible party type: Sponsor
mesh term: Carcinoma
mesh term: Carcinoma, Renal Cell
mesh term: Kidney Neoplasms
mesh term: Nivolumab
submitted: July 20, 2023
returned: August 10, 2023
submitted: August 16, 2023
returned: September 8, 2023